Purpose: Fludarabine has been reported to be the most effective single-agent in previously treated chronic lymphocytic leukaemia (CLL). Based on the in vitro synergism of fludarabine with anthracyclines and on results showing a higher efficacy of CHOP against COP we attempted to improve treatment results with a combination of fludarabine and an anthracycline.
Introduction
Chronic lymphocytic leukaemia (CLL) is characterised by a clonal expansion of B lymphocytes with a low proliferative activity but prolonged cell survival and an indolent low-grade clinical disease course. It is the most common adult leukaemia and despite a long-term survival of 3 to 10 years no curative treatment modalities are as yet available [1, 2] . Chlorambucil with or without prednisone is still the gold standard in the first-line therapy of CLL with remission rates of 45% to 85% but with few complete remissions (CR) [3, 4] .
Recently, new drugs such as purine analogues have shown significant activity in CLL [2, 5, [6] [7] [8] [9] . An especially promising drug in the treatment of CLL is fludarabine, a fluorinated purine analogue, the most widely studied such analogue. The present position of fludarabine is in the second-line therapy of CLL after failure on chlorambucil [6] [7] [8] [9] [10] . However, the latest results of Rai et al. [11] indicate that fludarabine should be included in the list of drugs with proven efficacy in the initial treatment of CLL. In this study fludarabine induced a higher overall and CR rate and a longer median duration of response than chlorambucil but did not prolong survival. Another recently published prospective randomised trial from the French Cooperative Group on CLL [12] comparing fludarabine versus CAP as first-line therapy indicated a higher response rate and a significantly longer progression-free survival (PFS) for patients treated with fludarabine. Based on the in vitro synergism of fludarabine with anthracyclines [13, 14] and on clinical results -such as those showing a higher efficacy of CHOP against COP [15] as well as a delayed response of fludarabine monotherapy in CLL with nodal manifestations [9] -it appears advisable to investigate a combination of fludarabine and an anthracycline in the attempt to further improve the response rate as well as long-term results. The aim of the present study was to evaluate the toxic effects as well as the efficacy of the combination of fludarabine and epirubicin in patients with advanced CLL.
Patients and methods
This study was an open phase II trial started in January 1994 in 13 participating centers. It was approved by the ethics committee of the university hospital of Frankfurt. All patients gave their written informed consent. The study was performed in accord with good clinical practice.
Eligibility criteria
Patients were eligible if they had a histologically confirmed diagnosis of CLL or leukaemic immunocytoma (peripheral lymphocytes >4.000/ul). They were required not to have received prior chemotherapy or to have a first relapse after prior treatment with one chemotherapy regimen not containing purine analogues, to have a performance status of ^ 2 and age between 18 and 70 years. Patients were staged using the Binet classification [16) according to the following procedure: physical examination, routine blood count, serum chemistry and determination of immunglobulin levels, CD4+ lymphocytes, chest X-ray, CT scan and sonography of the abdomen and bone marrow aspiration and biopsy. Patients with stages B or C in need of treatment as denned by an impairment of haematopoesis, the presence of B symptoms, very large lymph nodes, hepato-or splenomegaly or progressive disease were eligible for entry into the study.
Treatment
Fludarabine was administered at a dose of 25 mg/m 2 per day over five consecutive days by 30-minute infusion. Epirubicin was given at a dose of 25 mg/m 2 on days 4 and 5 by intravenous injection. This treatment was repeated every four weeks for a maximum of six cycles. If complete remission was achieved before the sixth cycle one additional consolidation cycle was administered. If progressive disease was ascertained, treatment was stopped. No prophylaxis for Pneumocystis carinii pneumonia (PCP) was given. month intervals until relapse. Patients with initial abdominal lymphomas had sequential CT scans during the follow-up period.
Patient characteristics
Forty-four patients entered the study between January 1994 and December 1996. Six patients were not evaluable due to protocol violations: two of these patients were excluded from the study after the first course of treatment after pathology review revealed a high-grade lymphoma, two patients discontinued therapy upon their own request after the first cycle due to a tumour lysis syndrome, one patient withdrew his consent due to poor peripheral veins, and one patient was treated with fludarabine as single-agent therapy only. The characteristics of 38 patients assessable for response and toxicity are listed in Table 1 .
Statistical methods
Overall survival was calculated from the first day of treatment to death. Duration of remission was the period from the beginning of remission to disease progression. Survival curves were estimated by the KaplanMeier method and the log-rank test was applied for comparison. Immunoglobulins were assessed by the Wilcoxon test before and after therapy.
Results

Criteria for response and toxicity
Response was assessed according to National Cancer Institute (NCI) working group criteria [17] . CR was defined as the disappearance of all palpable disease and the return to normal blood counts, with lymphocyte counts below 4.000/ul, granulocyte counts >1.500/ul, thrombocyte counts > 100.000/ul, and haemoglobin greater than 11.0 g/dl, as well as bone marrow lymphocyte percentage less than 30% in aspiration and biopsy material. PR required a greater than 50% reduction of measurable disease manifestations and a greater than 50% improvement in all abnormal blood counts. Treatment-related toxicity was evaluated according to the WHO criteria. Progression was defined by observation of one of the following criteria: a greater than 50% increase of circulating lymphocytes above remission values, a corresponding enlargement of lymph nodes, liver or spleen, or the appearance of new enlarged lymph nodes. Duration of remission was assessed through clinical and radiological examinations as well as blood counts at three-
Treatment response and progression-free survival
Overall 182 cycles were applied with a median of five cycles for each patient. The overall response rate in the 38 assessable patients was 82% (95% CI: 66%-92%) with a CR rate of 32% (95% CI: 18%-49%). For the 25 previously untreated patients (15 Binet B and 10 Binet C) the response rate was 92% (95% CI: 74%-99%) with a CR rate of 40% (95% CI: 21%-61%) with only two patients failing to obtain a response (Table 2) . Response (CR and PR) to treatment was achieved in 12 patients (39%) after the second, in an additional six patients (19%) after the third, and in 11 patients (36%) after the fourth courses, respectively. Patients with large involved lymph nodes showed especially rapid responses in some had low statistical power because of small numbers. The PFS curve is shown in Figure 1 . The median remission duration was 19 months (range 6-37 months) with 15 patients still in ongoing remission. Sixteen patients have relapsed to date after 6-37 months in remission.
Immunoglobulin (Ig) values before and after therapy were assessable for 24 patients. The initial median value for IgG increased from 679 mg/dl to 827 mg/dl after therapy (P = 0.001), for IgM from 51 mg/dl to 54 mg/dl (P = 0.21), and for IgA from 73 mg/dl to 76 mg/dl (P = 0.02), respectively. cases, with remission achieved in 37% after two courses and in 89% after four courses. Thirteen patients were treated in first relapse.
Survival
Prior treatment in 10 cases was chlorambucil with or without prednisone, and CHOP, COP or cyclophosphamide-monotherapy in one case each. The overall response rate for pretreated patients was 62% (95% CI: 32%-86%) with a CR-rate of 15% (95% CI: 2%-45%).
There was no statistical difference in the duration of PFS among CRs and PRs (P = 0.26), previously untreated and pretreated patients (P = 0.11), and patients with Binet stages B and C (P = 0.42), but the tests used To date 12 patients have died: seven pretreated patients of progressive disease, two patients suffering from multiple relapses of progressive disease, one patient after being treated for first refractory relapse, one patient at the age of 65 years due to a cerebral stroke in his first relapse 12 months after therapy, and one patient pneumonia during his first CR. The overall survival curve is shown in Figure 1 . The median survival was 33 months. The difference in duration of overall survival between previously untreated and pretreated patients with, for the untreated, an as yet unreached median survival, and 28 months for preatreated patients, is considered not quite significant (P = 0.06). There was no statistical difference in duration of survival between patients with Binet stages B and C (P = 0.22).
Acute toxicity
Nonhaematological toxicity was generally mild, mainly restricted to WHO grades 1 and 2. Nausea arid vomiting was rare and mild. No patient presented alopecia. There were no treatment-related deaths. One bacterial pneumonia during granulocytopenic phase and seven herpes zoster infections have been observed. As anticipated, granulocytopenia was the most common side effect noted. Grade 3 occurred in 36 (23%) and grade 4 occurred in 27 (17%) of 160 for toxicity evaluable cycles. No other severe infections were observed because of consistent and promp haematologic recovery. Grades 3 or 4 thrombocytopenia was rather rare and occurred only in 10 (6%) of all evaluable cycles (Table 3) . Fludarabine and epirubicin did not have cumulative haematotoxicity: granulocytopenia WHO grade > 3 was observed in 15 of 38 patients (39%) after cycle 1, in 12 of 33 patients (36%) after cycle 3 and in 5 of 18 patients (28%) after cycle 6. CD4 lymphocytes decreased in every case with a median of 1.913/ul before treatment, 783/ul after two, 290/ul after four, and 213/ul after six cycles. No CLL-related and no fludarabine-induced autoimmune haemolytic anaemia (AIHA) were observed during treatment. Two patients discontinued therapy on their own accord after the first cycle due to tumour lysis syndromes; both of them had high tumour burdens with high initial leucocyte counts, and developed grade 3 renal toxicity with elevated creatinine. Treatment was prematurely discon- tinued in two patients due to toxicity, in one of them consisting of a prolonged CD4-lymphocytopenia below 100/|il after four cycles (criteria for discontinuation according to protocol), and in the second patient because of the development of congestive heart failure with an ejection fraction of 20% after two cycles of fludarabine and epirubicin, which is equivalent to a cumulative dose of 100 mg/m 2 epirubicin. No initial ultrasound cardiogram was done. In the history of the latter patient a former excessive consumption of alcohol was determined.
Long-term toxicity
One patient developed a bacterial pneumonia with fatal outcome. He was in continuous first CR for nine months after being treated with four courses. No other significant infections were seen during the period between the cessation of therapy and initiation of salvage therapy.
Discussion
Thus far no curative approach to the treatment of CLL has been developed. Due to the slowly progressive clinical course in most cases it is widely accepted that patients should not be treated until the occurrence of diseaserelated symptoms but instead followed according to the 'watchful waiting' approach. The most commonly used chemotherapeutic drug in CLL is chlorambucil with or without prednisone [18] . Responses with this therapy range from 38% to 87% depending on the different drug dose schedules and prognostic parameters, but with achievementy of only a few CRs [2-4, 9, 10] . More aggressive regimens such as combinations of cyclophosphamide, vincristine and prednisone (COP) or with the addition of doxorubicin (CHOP) have been reported to induce higher response rates in advanced CLL but as yet they have shown no clear potential for improving survival [4, 15, 21, 22] .
The introduction of purine analogues has enlivened the entire area of clinical research in CLL. The most extensively studied purine analogue in CLL is fludarabine which is considered the drug with the highest therapeutic activity as single-agent [23] . Although thus far no significant survival advantage has been demonstrated for it over those of other regimens, it is obvious that fludarabine can achieve a high rate of complete response and long-lasting remissions in a large number of patients with a good quality of life and low incidence of infectious complications when used as first-line therapy [9, 10, 12, 15, 23] . As occurs with all antineoplastic drugs with proven single-agent activity in both pretreated and previously untreated patients, the next area for clinical research is its combination with other agents to further improve treatment results. Since single-agent fludarabine produced high complete remission rates, interest has grown in combining it with other agents to achieve higher rates of complete remission. Such an effective treatment strategy could make high-dose chemotherapy with stem cell rescue feasible as a first step in a potential cure.
Only a few combinations of fludarabine with other active agents in CLL have been studied and the list of drugs suitable for combination with fludarabine in CLL is short. Only for alkylating agents and corticosteroids has clinical activity been proven [24] . Fludarabine combined with chlorambucil has been associated with marked and persistent myelosuppression and increased toxicity without improved response [10, 25] . Although there is no evidence that prednisone can increase response rate or survival when combined with alkylating agents, O'Brien investigated the combination of fludarabine and prednisone in a large cohort of patients with CLL. The response and survival rates were not significantly different from those of fludarabine as a single-agent [26] . Anthracyclines such as doxorubicin or mitoxantrone have been demonstrated to be active in low-grade lymphomas but not to have a high level of activity in patients with CLL [24] . Combinations of fludarabine and mitoxantrone with dexamethasone showed a high response rate in low-grade lymphoma [27] , but have been explored in CLL by the same group with a response rate no different from that with fludarabine as a single-agent [24] . Montserrat demonstrated a high response rate in a small group of 18 patients with resistant or relapsed CLL using a combination consisting of fludarabine, cyclophosphamide and mitoxantrone (FCM) [28] . Promising results have been shown by a group from the MD Anderson Cancer Center. They achieved a response rate of 79% with the combination of fludarabine and cyclophosphamide in relapsing or refractory patients who received fludarabine for CLL [29] . There are reports of fludarabine-refractory patients who had some response to the combination of fludarabine with doxorubicin [30] , and the French Cooperative group on CLL showed a higher efficacy of the anthracycline-containing regimen CHOP compared to COP [15] , demonstrating a possible benefit of the addition of an anthracycline to treatment approaches in CLL.
The choice of epirubicin (4'-epidoxorubicin) instead of doxorubicin as the anthracycline in our study represents an attempt to decrease the risk of therapy-induced cardiotoxicity which is associated with therapy with anthracyclines. Epirubicin is dosed in the same fashion as doxorubicin and appears to be similar to doxorubicin in terms of antitumour activity [31] . The cardiotoxicity is significantly less than that of doxorubicin [32] [33] [34] , -a major concern, as most patients with CLL are elderly patients.
Our results show that the combination of fludarabine and epirubicin comprises a very effective CLL treatment in untreated patients and in the treatment of patients in first relapse. With the addition of epirubicin to fludarabine, it seems possible to achieve a higher response rate and a rapid response, especially of nodal manifestations of CLL. Because of its mild toxicity the regimen presented here can be administered in an outpatient facility except for the first cycle due to the possibility of the tumour lysis syndrome in patients with initial high lymphocyte counts or high tumour burden [9, 19] . Therefore, the first cycle should be performed in the ward to allow for monitoring for possible tumour lysis syndrome. Heavily pretreated patients are reported to have an increased risk of infection [10, 20] . Here, the combination of fludarabine plus epirubicin did not lead to an increased incidence of infections in the previously untreated or minimally pretreated patient group, which is in accordance with the data of the French Cooperative Group on Chronic Lymphocytic Leukaemia [12] using fludarabine as first-line therapy.
Whether the addition of an anthracycline to fludarabine can improve the clinical results in the treatment of CLL has to be verified by a randomised trial. The objectives of this already initiated study are to compare response rate, duration of remission and toxicity as well as overall survival of both fludarabine mono-and combination therapies. In addition, cytogenetic aberrations will be investigated in all patients to evaluate whether special chromosomal abnormalities are associated with prognosis and response to fludarabine. It will be of particular interest to observe whether there will be a higher response rate and a longer duration of remissions for the combination therapy in this ongoing study. The presented data suggest that the combination of fludarabine with epirubicin may improve the treatment of CLL without considerably increased toxicity, but whether this can result in a therapeutic benefit with higher remission rates and longer duration of remissions must be verified by the ongoing randomised study. To date, no trial has defined a survival advantage for fludarabine [35] , so fludarabine-based chemotherapy regimens are not yet part of the standard treatment for CLL. Their role in CLL management should be assessed in further clinical trials, such as the previously-cited study initiated by our group.
